LipoScience, Inc. Release: Clinical Data Suggests That Type 2 Diabetics with Low Cholesterol May Have Residual Cardiovascular Risk

RALEIGH, N.C.--(BUSINESS WIRE)--LipoScience, Inc., an in-vitro diagnostic company advancing patient care in cardiovascular, metabolic and other diseases using an innovative and proprietary platform based on nuclear magnetic resonance (NMR) technology, recognizes a presentation of clinical data which suggests that type 2 diabetics with low non-HDL and low LDL cholesterol may carry residual risk of a cardiac event based on high LDL particle numbers. The data was presented at the 2011 American Heart Association Scientific Sessions, now underway in Orlando, Florida.